Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP‐1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial
Sep 2026· Diabetes, obesity and metabolism· Vol 28, pp. 11463 - 11474· 0 citations· 23 references
Medicine
Abstract
To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of the dual GLP‐1R/GIPR agonist BGM0504 in Chinese adults with overweight or obesity without diabetes.
Dual glucagon‐like peptide‐1/glucagon receptor (GLP‐1/GCGR) agonists represent a novel obesity treatment class, but existing meta‐analyses often conflate them with GIP‐containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class‐specific efficacy and safety incompletely character...
M. Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al.· Diabetes, obesity and metabo...· 0 citations
This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors.
K. He, Yi-Lin Wei, Heng-Li Zhao et al.· Diabetes, obesity and metabo...· 0 citations
To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.
Jun-Sung Moon, K. Han, Dong-Lim Kim et al.· Diabetes, obesity and metabo...· 0 citations
This study assessed the real‐world effectiveness and safety of a fixed‐dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM).
Wei-Jian Ke, Ying-Hong Kong, Song-Bo Fu et al.· Journal of Diabetes· 0 citations
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of disconti...
Vikash Singhani, M. Ehsan, Sara Valencia et al.· Nutrition in clinical practi...· 0 citations
Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population r...
Hussain Salim, Shaheer Qureshi, G. Gulsin et al.· Diabetes, obesity and metabo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.